FDA Peptides Review: Access, Patient Education, and Whole-Health Models

👀 Is this healthcare’s next multibillion-dollar market? The regulatory landscape just shifted. Yesterday, an FDA advisory committee voted to recommend adding four widely discussed peptides to the Section 503A Bulks List: ✅ BPC-157 ✅ KPV ✅ TB-500 ✅ MOTS-c The votes were close, and they ran contrary to FDA staff recommendations citing limited evidence & unresolved safety concerns. That tension is important. These substances are not FDA-approved, and the votes do not immediately legalize or authorize their compounding. The committee’s recommendations are advisory, and additional FDA action is still needed. But the direction is meaningful. Consumer demand already exists across recovery, inflammation, metabolic health, energy & longevity. Much of that demand is currently being served through gray-market channels with inconsistent clinical oversight, sourcing & quality controls. A clearer regulatory pathway could begin moving this category toward licensed pharmacies, clinician supervision & more accountable healthcare platforms. The market is already paying attention: • Empower Pharmacy founder & CEO Shaun Noorian traveled to attend the meeting in person. You should give him a follow. • @hims & hers has publicly expressed interest and owns a U.S. peptide manufacturing facility. • 10X Health System has advocated for a regulated, traceable medical framework. • HALL HEALTH AND LONGEVITY CENTER has publicly supported greater accountability through the 503A pathway. • Alliance for Pharmacy Compounding has urged the FDA to consider safeguards and regulated access instead of broad restrictions. As the science, regulation & market develop, the central question will be whether consumer demand can be met through a model built around evidence, quality, clinical oversight & responsible access. Today, July 24, the committee turns to DSIP/Emideltide, Epitalon & Semax. I’ll share verified results in the comments as they become available. 💬 What role do you think established healthcare organizations should play as this category develops? FDA meeting materials: https://lnkd.in/gV6M5nTy Forbes: https://lnkd.in/gBSja9NT #Healthcare #DigitalHealth #Peptides #HealthcareInnovation #RegulatoryStrategy

Immunoglobulin therapy continues to play an important role in infusion and specialty pharmacy. As immunoglobulin utilization expands, providers face evolving considerations around product availability, purchasing strategies, inventory planning and patient care. Understanding the broader Ig landscape can help organizations make more informed decisions and better prepare for what’s ahead. Our latest blog explores immunoglobulin therapy, the trends shaping the market, and what infusion providers should know as they plan for the future. Read the blog: https://lnkd.in/ekiZFFKY #IVIG #SCIG #infusionpharmacy #specialtypharmacy #immunoglobulin

Back in April, I shared an article highlighting that the FDA was expected to ease restrictions on several popular peptides in the coming months. That change is actually happening now. A FDA advisory panel recently voted to allow specialized compounding pharmacies to produce compounds like BPC-157, TB-500, and KPV for prescription use. If you closely follow developments in healthcare and wellness, these names likely sound familiar.  Over the past couple of years, interest in these peptides has surged for everything from gut health and tissue repair to recovery. However, because they weren't approved for human consumption, consumers were often sourcing them through unregulated online channels. What makes this recent vote particularly interesting is the rationale behind it. The panel's decision wasn't driven by a sudden flood of new clinical trial data, which remains limited, but rather by a push for safer access and quality control, moving these compounds out of a regulatory gray market and into licensed pharmacies. While the FDA still needs to grant final approval, this represents a significant pivot in how regulatory bodies approach high-demand, emerging health therapies. It will be compelling to watch how mainstream medicine adapts as patient demand meets official clinical pathways. How do you see this decision impacting the broader landscape of preventive health and compounding pharmacy regulation? #Peptides #BPC157 #TB500 #FDA #CompoundingPharmacy #HealthcareRegulation #PreventiveHealth #FunctionalMedicine #HealthPolicy #HealthcareInnovation

Over the past several years, peptide therapies have generated significant interest from patients, providers, researchers, and regulators alike. The conversations have been passionate. Sometimes controversial. But perhaps we've been asking the wrong question. Instead of asking, "Should peptides be available?" Perhaps we should be asking, "How do we responsibly evaluate emerging therapies while protecting patients and preserving access to individualized care?" That is why this week's activity at the Pharmacy Compounding Advisory Committee (PCAC) is worth paying attention to. The committee's recommendation to include BPC-157, KPV, TB-500, and MOTS-c on the proposed Section 503A Bulks List does not make these substances FDA-approved therapies. Nor does it immediately authorize their use in compounded medications. What it does represent is something equally important. A willingness to continue evaluating whether certain therapies deserve a place within a regulated, patient-specific healthcare framework. That distinction matters. Personalized medicine has never been about offering every new therapy. It has always been about balancing three responsibilities: • Scientific evidence • Regulatory oversight • Individual patient need Those principles should never compete with one another. They should work together. As compounding pharmacists, we believe innovation should move forward—but it should move forward responsibly, transparently, and with patients at the center of every decision. Whether the FDA ultimately accepts or rejects these recommendations, one thing is becoming increasingly clear. Healthcare is moving away from a one-size-fits-all model. Providers are asking more individualized questions. Patients are seeking more personalized solutions. And the regulatory conversation is evolving alongside them. At Olive Tree Compounding Pharmacy, we'll continue following these developments closely, supporting evidence-based discussions, and partnering with providers to deliver patient-specific care within the framework established by federal and state regulations. #PersonalizedMedicine #503ACompounding #CompoundingPharmacy #HealthcareInnovation #PatientCenteredCare #PharmacyLeadership

At Olive Tree Compounding Pharmacy, we'll continue following these developments closely, supporting evidence-based discussions, and partnering with providers to deliver patient-specific care within the framework established by federal and state regulations.

A Big Week for the Future of Pharmacy-Compounded Peptides Tomorrow, the FDA's Pharmacy Compounding Advisory Committee (PCAC) begins a two-day meeting to review several peptides that could shape the future of pharmacy compounding. So what does that mean? It is NOT an approval or denial. Instead, an independent panel of experts will review the available science and make recommendations to the FDA. Those recommendations help guide the FDA's final decisions, but they are not the final ruling. At Gameday Men's Health Solon, we're following these discussions closely because we believe patients deserve access to treatments that are: ✔️ Prescribed by licensed medical providers ✔️ Dispensed by regulated U.S. compounding pharmacies ✔️ Backed by quality standards and medical oversight ✔️ Never sourced from the unregulated "research chemical" market No matter what the committee recommends, our commitment doesn't change. We'll continue to focus on patient safety, education, and evidence-based care while working with trusted pharmacy partners. We'll be watching the meeting over the next two days and will share updates as more information becomes available. Real Team. Real Medicine. Real Life Solutions. 📍 Gameday Men's Health Solon 📞 440-201-4919 🌐 Complimentary Consultations Available #GamedayMensHealth #SolonOH #Peptides #FDA #CompoundingPharmacy #PatientSafety #MensHealth #HormoneHealth #EvidenceBasedMedicine #Wellness

👀 If you're in aesthetics, wellness, or longevity medicine... this is one FDA meeting you should be watching. The FDA's Pharmacy Compounding Advisory Committee is still meeting today, and yesterday's votes were a major development. The committee voted to recommend broader access for BPC-157, KPV, TB-500, and MOTS-c—a significant step for the peptide industry. While these votes are advisory (not final FDA approval), they could shape the future of peptide compounding and availability through 503A pharmacies. Today's agenda includes additional peptides, and the outcomes could have a meaningful impact on clinics, providers, and patients alike. This is one of the biggest peptide discussions we've seen in years... and it's not over yet. 🍿 I'll definitely be watching. Will you? #Peptides #LongevityMedicine #MedicalAesthetics #RegenerativeMedicine #Wellness #CompoundingPharmacy #MedSpa #HealthcareInnovation

Efficacy opens the door. Access builds the market. The FDA approval of Lipfendra, the first oral PCSK9 inhibitor, is more than a formulation milestone. The clinical signal is strong: 3,207 adults across two randomized Phase 3 trials, with LDL-C reductions of 56% and 59% at Week 24. But the business question is different. PCSK9 inhibitors have already shown powerful LDL-C lowering. The harder problem has been conversion: Eligible patient → prescription → insurer approval → filled therapy → persistence. Historical PCSK9 data show how much value can be lost inside that funnel: Only 47.2% of new PCSK9 prescriptions received insurer approval, and only 30.9% ultimately reached therapy. That is why oral delivery matters. Not because it creates the patient pool. The patient pool already exists. It matters because it may reduce injection reluctance, administration burden, and prescriber workflow friction. Still, oral format alone will not determine market scale. The next questions are: - Will payers support access? - Will copay barriers remain manageable? - Will daily persistence hold up in real-world use? - Will cardiovascular outcomes data support broader adoption? #FDA #Lipfendra #PCSK9 #CardiovascularDisease #LDLCholesterol #PharmaStrategy #MarketAccess #Biotech #HealthcareInnovation

Following the FDA advisory panel's vote, peptides remain a key topic of discussion.   Hear from our CEO and Co-Founder, Elizabeth Philp, as she shares her insights on the latest developments and what this means for the UK and the USA.    Read more over on our blog: https://lnkd.in/e4_2Zp5f   #Peptides #RosewayLabs #CompoundingPharmacy #CompoundedMedication #Healthcare 

Could shorter treatment visits improve the patient experience in MS care? New findings suggest patients overwhelmingly favored a newer subcutaneous formulation of ocrelizumab, while also highlighting the important role of pharmacy-led care coordination. Read more: https://lnkd.in/gZJ3erjG #MultipleSclerosis #HealthcareInnovation #SpecialtyPharmacy #pharmacy #MS #healthcare